CD8A and Thrombocytopenia: Additionally, the combination therapy reduced CD8<sup>+</sup> levels and mitigated abnormal laboratory indicators caused by chemotherapy, such as leukopenia, thrombocytopenia, decreased hemoglobin, and abnormal liver and kidney function.